Parkside Financial Bank & Trust Grows Holdings in GSK plc (NYSE:GSK)

Parkside Financial Bank & Trust increased its stake in shares of GSK plc (NYSE:GSK) by 470.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 992 shares of the pharmaceutical company’s stock after purchasing an additional 818 shares during the period. Parkside Financial Bank & Trust’s holdings in GSK were worth $34,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in GSK. Gladstone Institutional Advisory LLC grew its stake in shares of GSK by 13.6% in the third quarter. Gladstone Institutional Advisory LLC now owns 11,814 shares of the pharmaceutical company’s stock valued at $483,000 after buying an additional 1,410 shares in the last quarter. Van ECK Associates Corp grew its position in GSK by 8.4% in the 3rd quarter. Van ECK Associates Corp now owns 736,510 shares of the pharmaceutical company’s stock valued at $27,973,000 after acquiring an additional 56,843 shares in the last quarter. BSW Wealth Partners purchased a new stake in GSK during the third quarter worth about $223,000. Forum Financial Management LP acquired a new stake in shares of GSK during the third quarter worth about $204,000. Finally, KG&L Capital Management LLC boosted its stake in shares of GSK by 44.1% in the third quarter. KG&L Capital Management LLC now owns 16,685 shares of the pharmaceutical company’s stock valued at $679,000 after purchasing an additional 5,104 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Performance

Shares of GSK opened at $37.97 on Tuesday. The company has a market capitalization of $78.70 billion, a price-to-earnings ratio of 23.88, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The stock has a 50 day moving average price of $35.07 and a 200 day moving average price of $37.20.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Research analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.14%. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is 98.74%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on GSK shares. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley initiated coverage on shares of GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.